Bank of America
ABCL icon

Bank of America’s AbCellera Biologics ABCL Stock Holding History

Bank of America’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.2M Buy
6,141,539
+3,141,603
+105% +$15.4M ﹤0.01% 1731
2026
Q1 		$10.5M Buy
2,999,936
+367,064
+14% +$1.32M ﹤0.01% 2913
2025
Q4 		$9M Buy
2,632,872
+214,568
+9% +$958K ﹤0.01% 2935
2025
Q3 		$12.2M Buy
2,418,304
+2,193,939
+978% +$9.67M ﹤0.01% 3105
2025
Q2 		$770K Buy
224,365
+208,390
+1,304% +$519K ﹤0.01% 5460
2025
Q1 		$35.6K Sell
15,975
-1,166
-7% -$3.34K ﹤0.01% 6826
2024
Q4 		$50.2K Sell
17,141
-1,936
-10% -$5.39K ﹤0.01% 6637
2024
Q3 		$49.6K Buy
19,077
+8,837
+86% +$24.5K ﹤0.01% 6545
2024
Q2 		$30.3K Sell
10,240
-146,843
-93% -$556K ﹤0.01% 6642
2024
Q1 		$712K Sell
157,083
-14,433
-8% -$73.6K ﹤0.01% 5137
2023
Q4 		$979K Sell
171,516
-5,018
-3% -$23.3K ﹤0.01% 4998
2023
Q3 		$812K Buy
176,534
+133,771
+313% +$814K ﹤0.01% 4971
2023
Q2 		$276K Sell
42,763
-122,598
-74% -$837K ﹤0.01% 5626
2023
Q1 		$1.25M Buy
165,361
+67,932
+70% +$617K ﹤0.01% 4763
2022
Q4 		$987K Buy
97,429
+21,067
+28% +$243K ﹤0.01% 4869
2022
Q3 		$756K Buy
76,362
+31,984
+72% +$351K ﹤0.01% 5085
2022
Q2 		$473K Buy
44,378
+32,734
+281% +$277K ﹤0.01% 5471
2022
Q1 		$113K Buy
11,644
+7,536
+183% +$71.4K ﹤0.01% 6787
2021
Q4 		$59K Buy
4,108
+1,661
+68% +$25.2K ﹤0.01% 7141
2021
Q3 		$49K Sell
2,447
-84,269
-97% -$1.49M ﹤0.01% 7051
2021
Q2 		$1.91M Buy
86,716
+86,715
+8,671,500% +$2.39M ﹤0.01% 4366
2021
Q1 		$0 Buy
+1
New +$40 ﹤0.01% 7379

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Bank of America's ABCL Position: Q2 2026 in Review

Bank of America increased its AbCellera Biologics (ABCL) stake by 105% in Q2 2026, buying an estimated $15.4M and bringing the position to 6,141,539 shares worth $48.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1731.

Bank of America first reported a position in ABCL in Q1 2021 and has held it in 22 quarters since. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Bank of America held 6,141,539 shares of AbCellera Biologics worth $48.2M as of Q2 2026.
  • Bank of America bought 3,141,603 AbCellera Biologics shares in Q2 2026, an estimated $15.4M.
  • AbCellera Biologics made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #1731 holding.
  • Bank of America first reported a position in AbCellera Biologics in Q1 2021 and has held it in 22 quarters since.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.